Data of this work indicate that miR-362 is an integral part of the TGF-β/SMAD signaling pathway, and that miR-362 is the driver of a previously-unreported SMAD4/E-cadherin/miR-362 axis in modulating the EMT and MET processes, and, therefore, cell motility and invasiveness in cancers, superseding other reported miR-362 targets in explaining miR-362 suppression of metastasis 8, 12, 13, 16, 19-21. Here, TGFB1 is linked to cancer.